Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis

Table 1

Base data of MDR-TB patients.

Type of sample	Age (year)	Gender	Weight (kg)	AFB	Mtb culture	TB DNA	Drug resistance	Treatment history^#
CIK plus
	44	Male	79	1+	Positive	No	SRRSBBBB	AmMfxPtoRfbCfzClrPa
	34	Female	48	3+	Positive	No	RRRRSSRR	AmLfxPtoZPas
	32	Male	65	1+	Positive	No	RRRRRSSS	No treatment
	73	Male	70	4+	Positive	No	RRRRSRSR	PaRfbMfxZPtoClr
	27	Male	55	5+	Positive	No	SRRSSSSS	ZEAmLfxPto
	26	Male	60	1+	Positive	No	RRRRRSRS	PaZPtoClrAm
	59	Male	60	2+	Positive	No	SRSSRSSR	PaRftLfxZ
	62	Female	46	2+	Positive	No	SRRSSSSR	PasEZPto
	25	Female	51	5+	Positive	No	SRRSBBBB	PaRfbMfxZPtoClr
Chemo-mono
	34	Female	63	1+	Positive	No	SRRSBBBB	HZPasAmLfxPto
	64	Female	52	3+	Positive	No	RRRRBBBB	No treatment
	30	Male	56	4+	Positive	No	RRRSBBBB	ELfxClrPto
	46	Male	50	4+	Positive	No	RRRSSRSR	CmPasLzdCfzAmx/ClvPtoE
	25	Male	62	2+	Positive	No	SRRSBBBB	ZAmLfxPtoPas
	18	Female	36.5	4+	Positive	No	RRRSBBBB	ZAmLfxEPasPto
	66	Male	51	3+	Positive	No	RRRRSSSR	PaRftEZ
	48	Male	65	3+	Positive	No	RRRSRSRR	PasZPtoClrMfx
	24	Male	55	3+	Positive	No	RRRSSSSS	HPasEZPtoAm

Drug resistance: S—sensitive, R—resistance, and B—blank (not tested). Drug resistance order: SM, INH, RFP, EMB, Pas, Am, Pto, and Lfx. ^#Antituberculosis drug abbreviation: Am: amikacin; Lfx: levofloxacin; Mfx: moxifloxacin; SM: streptomycin; H/INH: isoniazid; RFP: rifampicin; E/EMB: ethambutol; Pas: para-aminosalicylic acid; Pa: pasiniazid; Pto: protionamide; Rfb: rifabutin; Rft: rifapentine; Cm: capreomycin; Lzd: linezolid; Amx/Clv: amoxicillin and clavulanate potassium; Cfz: chloroformin; Clr: clarithromycin; Z: pyrazinamide.